Company intelligence / Profile preview
Velicept Therapeutics
Wayne, Pennsylvania, United Statesvelicept.com ↗
- Ownership
- Private
- Employees
- ~3000
- Development stage
- Other
01
Overview
Solabegron demonstrated significant improvement in Phase II studies for OAB compared to placebo, with reduction in wet episodes and daily voids. In IBS studies, it showed significant reduction in pain and a trend for improved quality of life. Both studies indicated a tolerability profile similar to placebo[4].
- Therapeutic areas
- GastroenterologyUrology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Velicept Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Velicept Therapeutics.